{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:46:51Z","timestamp":1761176811112,"version":"build-2065373602"},"reference-count":16,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. Cardiac amyloidosis is an underdiagnosed disease, and its prevalence is probably higher than previously estimated. We aimed to investigate the effect of introducing a systemic diagnostic algorithm for cardiac amyloidosis in clinical practice.\n\nMETHODS. A systematic diagnostic algorithm was developed and clinically applied in two hospitals in Eastern Denmark. Elderly patients (males &gt; 60 years, females &gt; 70 years) with left ventricular hypertrophy (\u2265 12 mm) and diastolic dysfunction leading to a suspicion of cardiac amyloidosis were referred for standardised workup, including biochemistry and bone scintigraphy.\n\nRESULTS. A total of 224 patients (median age 76 years (70-83); 65% males) were included in the analysis. In total, 43 (19%) patients (84% males) were diagnosed with cardiac amyloidosis. Among the 43 diagnosed patients, 38 had transthyretin wild-type amyloidosis, one had the hereditary form and four had monoclonal-immunoglobulin-light-chain amyloidosis. Patients with cardiac amyloidosis were significantly older (81 versus 75 years old, p &lt; 0.001) and more often male (84% versus 61%, p = 0.004) than the overall screened population.\n\nCONCLUSIONS. Systematic screening for cardiac amyloidosis in older patients with cardiac hypertrophy and echocardiographic signs of diastolic dysfunction is feasible and shows a diagnostic yield of 19% in the assessed population.\n\nFUNDING. None.\n\nTRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a11240771","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:32:36Z","timestamp":1756902756000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Clinical experience of a systemic algorithm for diagnosis of cardiac amyloidosis"],"prefix":"10.61409","author":[{"given":"Julie Bjerre","family":"Tarp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Bayer","family":"Elming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisbeth","family":"Marner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Haarmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex H\u00f8rby","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Jakob","family":"Thune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-2594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-1212. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.843334","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhao L, Fang Q. Recent advances in the noninvasive strategies of cardiac amyloidosis. Heart Fail Rev. 2016;21(6):703-721. https:\/\/doi.org\/10.1007\/s10741-016-9580-5","DOI":"10.1007\/s10741-016-9580-5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-670. https:\/\/doi.org\/10.1016\/j.jcmg.2011.03.016","DOI":"10.1016\/j.jcmg.2011.03.016"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6((6):1128-1139. https:\/\/doi.org\/10.1002\/ehf2.12518","DOI":"10.1002\/ehf2.12518"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16-26. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-2594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8):e005066. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005066","DOI":"10.1161\/CIRCIMAGING.116.005066"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879-2887. https:\/\/doi.org\/10.1093\/eurheartj\/ehx350","DOI":"10.1093\/eurheartj\/ehx350"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8(9):712-724. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007","DOI":"10.1016\/j.jchf.2020.04.007"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Rasmussen TB, Ladefoged BT, Dybro AM, et al. Transthyretin gene variants and associated phenotypes in Danish patients with amyloid cardiomyopathy. Cardiogenetics. 2022;12(1):1-11. https:\/\/doi.org\/10.3390\/cardiogenetics12010001","DOI":"10.3390\/cardiogenetics12010001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022;9(5):e340-e349. https:\/\/doi.org\/10.1016\/S2352-3026(22)00069-2","DOI":"10.1016\/S2352-3026(22)00069-2"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:38Z","timestamp":1761129218000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A11240771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":16,"URL":"https:\/\/doi.org\/10.61409\/a11240771","relation":{},"ISSN":["2245-1919"],"issn-type":[{"type":"electronic","value":"2245-1919"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}